Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €2.31 EUR
Change Today 0.00 / 0.00%
Volume 0.0
ABB On Other Exchanges
As of 11:39 AM 04/27/15 All times are local (Market data is delayed by at least 15 minutes).

ab-biotics sa (ABB) Snapshot

Previous Close
Day High
Day Low
52 Week High
05/22/14 - €2.84
52 Week Low
10/16/14 - €1.55
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for AB-BIOTICS SA (ABB)

Related News

No related news articles were found.

ab-biotics sa (ABB) Related Businessweek News

No Related Businessweek News Found

ab-biotics sa (ABB) Details

AB-BIOTICS SA, a biotechnology company, is engaged in the research and development of pharmacogenetic tests for neuropsychiatry, and probiotics and other functional ingredients for the food and pharmaceutical industries. Its marketed products include AB-LIFE, a probiotic product that reduces the risk of cardiovascular disease by normalizing serum lipids, reducing vascular inflammation, and lowering blood pressure; AB-FORTIS, an iron-containing ingredient with a double-coat microencapsulation, which allows the fortification of foods with iron without the risk of generating undesirable byproducts, such as oxidized lipids that are caused by iron-mediated oxidation; and AB-DENTALAC, a probiotic product designed to fight the oral pathogens causing caries, gingivitis, and halitosis or bad breath. The company’s clinical products comprise AB-I3.1 that reduces the symptoms and the frequency of gastrointestinal emergencies in patients affected by IBD and IBS; AB-COLIC, which is designed to be orally administered in an oil-based solution, with broad antagonism for pathogens present in breast milk and infant formula; AB-INTIMUS, a probiotic with ability to adhere to the vaginal epithelium and displace candida infections; AB-GINGIBAL designed to enhance gum health in patients suffering from gingivitis; AB-HALITIOSIS that rids the oral cavity of unwanted microorganisms and helps to rebuild microflora in the mouth; AB-ENHANCER, a probiotic alternative; AB-RADIOBAL, a probiotic formula designed to reduce the incidence of radiotherapy-induced diarrhea; AB-PROBIOSIS, a functional ingredient; AB-PYLORIOSIS; and AB-VITAMIN-K. It also provides Neuropharmagen, an analytical test for use in neurology and psychiatry that identifies an appropriate medication for each individual patient by analyzing their DNA; and outsourced research and development solutions to pharmaceutical companies, as well as functional food companies. The company is based in Barcelona, Spain.

ab-biotics sa (ABB) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

ab-biotics sa (ABB) Key Developments

AB-Biotics SA Presents at BIO-Europe Spring 2015, Mar-09-2015

AB-Biotics SA Presents at BIO-Europe Spring 2015, Mar-09-2015 . Venue: Paris Expo - Porte de Versailles, Hall 5, Paris, France.

AB-Biotics Agrees Distribution Deal with Abbott for I3.1 Probiotic in Spain

AB-Biotics has finalised a commercial agreement with Abbott Pharmaceuticals (US) to distribute, promote, and market I3.1 probiotic (a strain that targets bloating, gas formation, and pain). Abbott will handle the exclusive promotion of the I3.1 probiotic in Spain, while the Spanish biotechnology firm focuses on R&D and commercialising its personalised medical product pipeline. AB-Biotics has been expanding its system of granting licensing agreements with other companies since 2012. However, the tie-up with Abbott Pharmaceuticals marks the first licensing agreement for I3.1 probiotic in Europe.

DuPont Nutrition & Health and AB-Biotics Announce Agreement on Probiotic for Cardiovascular Health

DuPont Nutrition & Health and AB-Biotics have signed a global collaboration and licensing agreement on AB-Life, a probiotic that is clinically documented to maintain healthy levels of cholesterol in at-risk individuals. Under the agreement, DuPont will have exclusive rights for the production, marketing and sales of AB-Life; and AB-Biotics will continue to conduct clinical research to further substantiate the proven health benefits of AB-Life. AB-Life is a patented probiotic formulation developed by AB-Biotics, based in Barcelona, Spain. DuPont is integrating AB-Life into its documented HOWARU probiotic range for the dietary supplement and food and beverage industries. The company expects to launch the product in fourth quarter 2014.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ABB:SM €2.31 EUR 0.00

ABB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ABB.
View Industry Companies

Industry Analysis


Industry Average

Valuation ABB Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 8.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AB-BIOTICS SA, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at